Sign In
Buy SAGE
$8.68
+0 (+0%)
At Close: Oct 30, 2025
Sage Therapeutics' stock slides after biotech says it will cease development of Alzheimer's treatment
07:28am, Tuesday, 08'th Oct 2024
Sage Therapeutics Inc.'s stock tumbled 12.8% early Tuesday, after the company said a mid-stage trial of a treatment for mild cognitive impairment and mild dementia in Alzheimer's disease failed to mee
Lost Money on Sage Therapeutics, Inc.(SAGE)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
07:15am, Tuesday, 08'th Oct 2024
NEW YORK, NY / ACCESSWIRE / October 8, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities
NEW YORK CITY, NY / ACCESSWIRE / October 8, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sage Ther
Sage Therapeutics to discontinue development of Alzheimer's drug
06:40am, Tuesday, 08'th Oct 2024
Sage Therapeutics said on Tuesday it will discontinue the development of its Alzheimer's disease drug as it did not meet the main goal in a mid-stage trial.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) announced today topline results from LIGHTWAVE, a 12-week, Phase 2 randomized, double-blind, placebo-controlled study to evalu
Shareholders that lost money on Sage Therapeutics, Inc.(SAGE) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
05:45am, Tuesday, 08'th Oct 2024
NEW YORK , Oct. 8, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sage Therapeutics, Inc. ("Sage Therapeutics" or the "Company") (NASDAQ: SAGE) of a class action securities lawsuit.
NEW YORK, NY / ACCESSWIRE / October 7, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Sage Therapeutics, Inc. Lawsuit - SAGE
01:45pm, Monday, 07'th Oct 2024
NEW YORK, NY / ACCESSWIRE / October 7, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities
Sage Therapeutics Stock Down Almost 40% in 3 Months: Here's Why
01:31pm, Monday, 07'th Oct 2024
The pipeline setbacks related to SAGE's neurology candidate, SAGE-324, being developed for essential tremor, weigh heavily on the stock.
Investors who lost money on Sage Therapeutics, Inc. (SAGE) should contact Levi & Korsinsky about pending Class Action - SAGE
12:45pm, Monday, 07'th Oct 2024
NEW YORK, NY / ACCESSWIRE / October 7, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities
NEW YORK, NY / ACCESSWIRE / October 7, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities
LOS ANGELES, CA / ACCESSWIRE / October 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sage Therapeutics, Inc. ("Sage"
Investors in Sage Therapeutics, Inc. Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - SAGE
10:45am, Monday, 07'th Oct 2024
NEW YORK, NY / ACCESSWIRE / October 7, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities
NEW YORK, NY / ACCESSWIRE / October 7, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ:SAGE) and certain off
Shareholders that lost money on Sage Therapeutics, Inc. (SAGE) should contact Levi & Korsinsky about pending Class Action - SAGE
07:15am, Monday, 07'th Oct 2024
NEW YORK, NY / ACCESSWIRE / October 7, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities
